CBC Explained: The Science Behind Our New CBC Hard Candy
Most people familiar with hemp-derived cannabinoids have heard of CBD. Some are beginning to discover CBG and CBN. But there’s another naturally occurring cannabinoid that hasn’t received nearly as much attention: cannabichromene, better known as CBC.
CBC isn’t new. It’s been studied for decades, but compared to CBD and THC, our scientific understanding of it is still developing.
What makes CBC particularly interesting is the way it interacts with different biological systems, along with some promising findings from early laboratory and animal research.
At Big Cat Botanics, we believe CBC deserves more attention. That’s why we’re introducing our new Bomb Pop CBC Hard Candy, made with hemp-derived CBC isolate and our traditional hard candy recipe.
What Is CBC?
CBC stands for cannabichromene, a naturally occurring, non-intoxicating cannabinoid found in the cannabis plant.
Like CBD and THC, CBC develops from cannabinoid precursors produced by the plant. Its acidic precursor, CBCA, is formed from CBGA through an enzymatic process. CBCA can then convert into CBC through decarboxylation.
Although CBC comes from the same plant as THC, the two compounds have different chemical structures and pharmacological properties.
Unlike THC, CBC is not generally associated with intoxication.
Researchers are particularly interested in CBC because of its interactions with certain receptors and signaling pathways, including those involved in the body’s endocannabinoid system.
CBC may be less familiar than CBD, but that doesn’t make it any less interesting.
What Does the Research Say?
One thing we try to do at Big Cat Botanics is separate what we know from what we’re still learning.
CBC has demonstrated some interesting biological activity in laboratory and animal studies, particularly in research involving inflammation, receptor signaling, and mood-related behavior.
But there is an important distinction: most of this research is preclinical. We don’t yet have the human clinical evidence needed to establish what benefits CBC might provide.
That said, some of the findings are worth discussing.
A 2010 study published in Pharmacology, Biochemistry and Behavior examined several cannabinoids in animal models commonly used to investigate antidepressant-like activity.
Researchers observed that CBC produced statistically significant changes in certain behavioral tests involving mice. These findings suggested that CBC may influence biological pathways associated with mood regulation.
A 2025 study investigated CBC in another mouse model involving chronic stress. Researchers again observed changes in depression-related behavioral measures, along with several biological markers associated with the stress response.
These findings are interesting, particularly because they come from different experimental approaches.
However, animal studies cannot tell us whether CBC improves mood in humans, and they don’t establish an effective dose for people.
Researchers have also investigated how CBC interacts with receptors involved in inflammatory and sensory signaling.
A 2025 study published in Cannabis and Cannabinoid Research examined CBC’s activity at CB2 receptors and TRPA1 channels in laboratory experiments.
These biological targets are involved in several important physiological processes, and understanding how CBC interacts with them may help explain some of its distinctive properties.
A comprehensive scientific review published in 2026 brought together much of the available CBC research, highlighting its potential while emphasizing the substantial gaps in human clinical evidence.
The review also identified important questions about CBC absorption, metabolism, safety, and possible interactions with medications.
For us, the takeaway is pretty straightforward.
CBC is scientifically interesting, and the early research provides good reasons to continue studying it. But promising laboratory results aren’t the same thing as proven benefits in people.
We’re interested in the science, not exaggerating what it tells us.
Why Hard Candy?
This is where things get particularly interesting to us.
Most cannabinoid products are sold as gummies, capsules, oils, or tinctures. These are all familiar delivery methods, but the way a cannabinoid is consumed can influence how it is absorbed and processed by the body.
When a conventional gummy or capsule is swallowed, its contents travel through the digestive system before reaching circulation.
The mouth, however, provides another potential route for absorption.
The tissues inside the cheeks and beneath the tongue can allow certain compounds to enter circulation without first passing through the digestive system. These are known as buccal and sublingual absorption.
This isn’t a new concept. Oral mucosal delivery is already an established area of pharmaceutical science.
A 2026 review published in AAPS PharmSciTech examined oral mucosal cannabinoid delivery, including formulation challenges, contact time, and factors that influence absorption through oral tissues.
This is part of the reasoning behind our hard candy platform.
Unlike a gummy that’s typically chewed and swallowed, our hard candies are designed to dissolve gradually in the mouth.
As the candy dissolves, CBC is released over time, allowing prolonged contact with the tissues inside the cheeks and beneath the tongue.
Depending on the formulation and other factors, some absorption may occur through these tissues, while the portion that is swallowed follows the traditional digestive route.
There are important limitations to consider.
Cannabinoids are generally poorly soluble in water, and simply keeping a compound in your mouth longer doesn’t guarantee that more of it will be absorbed.
We haven’t conducted a pharmacokinetic study on our CBC hard candy, so we can’t claim a specific absorption rate, faster onset, or greater bioavailability compared with other cannabinoid products.
What we can say is that the scientific principles behind buccal and sublingual delivery are an important part of why we’re interested in slow-dissolving hard candy as a cannabinoid delivery platform.
And of course, there’s something to be said for enjoying a good piece of old-fashioned hard candy.
Introducing Our Bomb Pop CBC Hard Candy
Our newest CBC Hard Candy combines this delivery concept with a traditional confectionery experience.
Handcrafted in small batches in Colorado, these candies feature our Bomb Pop flavor, a slowly dissolving hard candy base, and hemp-derived CBC isolate.
Each 105 g package contains approximately 850 mg of CBC, with cannabinoid content verified through independent laboratory testing.
Like our other cannabinoid hard candies, each batch undergoes independent laboratory testing for cannabinoid potency and microbial contamination.
Our current batch has also been verified to contain no detectable THC according to its laboratory results.
We provide batch-specific Certificates of Analysis so customers can review the actual laboratory data, including cannabinoid potency and THC testing results.
We believe that customers deserve to know what’s actually in the products they’re purchasing.
For us, independent testing isn’t just a marketing point. It’s part of making products we’re comfortable putting our name on.
You can review the current batch details and laboratory results directly on our product page.
A Different Way to Explore CBC
CBC is one of the lesser-known cannabinoids, and there’s still a great deal we don’t understand about it.
That’s part of what makes it interesting.
While the early research has identified several promising areas for further investigation, we think it’s important to let the science develop without getting ahead of the evidence.
At Big Cat Botanics, we’re not interested in chasing trends or making exaggerated claims about what cannabinoids can do.
We’re interested in understanding these compounds, developing quality formulations, and making independently tested products that we can stand behind.
Our new CBC Hard Candy is another step in that direction.
If you’re curious about CBC, we encourage you to explore the research, review our laboratory results, and learn more about this unique cannabinoid.
Explore CBC Hard Candy at Big Cat Botanics
Scientific References
- El-Alfy, A. T., et al. (2010). Antidepressant-like effect of ?9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacology, Biochemistry and Behavior, 95(4), 434–442.
- Sharma, et al. (2025). Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations.
- Udoh, et al. (2025). Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene. Cannabis and Cannabinoid Research, 10(1), e94–e101.
- Elbouzidi, A., et al. (2026). Cannabichromene (CBC): a comprehensive review of biosynthesis, pharmacology, therapeutic potential, and translational perspectives. Journal of Cannabis Research, 8, 107.
- Nagaraj, A., & Seyfoddin, A. (2026). Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and Permeation Enhancement. AAPS PharmSciTech.
Disclaimer
This article is provided for educational and informational purposes only and is not intended as medical advice.
The scientific studies discussed in this article primarily involve laboratory experiments, animal models, and preliminary research. These findings should not be interpreted as evidence that CBC produces the same effects in humans. The studies referenced did not evaluate Big Cat Botanics products, and no clinical studies have been conducted to establish the absorption rate, bioavailability, or therapeutic effectiveness of our CBC Hard Candy.
Big Cat Botanics products are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the U.S. Food and Drug Administration (FDA).
Individuals who are pregnant, nursing, taking medications, or managing a medical condition should consult a qualified healthcare professional before using cannabinoid products.
Cannabinoid research is ongoing, and the information presented here reflects the scientific literature available at the time of publication.